In August 2019, Professor Ryuhei Hayashi, Professor Koji Nishida, and co-workers from the Graduate School of Medicine, Osaka University, reported the world’s first transplantation of a corneal epithelial sheet-derived from induced pluripotent stem (iPS) cells. Corneal epithelial sheets from HLA-homozygous iPS cells were produced and transplanted into patients with corneal epithelial stem cell deficiency. The clinical study was approved by the Japanese government in March 2019 and the first transplant was performed in July 2019 with four transplantations planned in total. In the first study, safety was evaluated as the primary endpoint, and efficacy such as improvement of symptoms and visual acuity were evaluated as secondary endpoints.
Ajinomoto Co., Inc. provides “StemFit”, iPS / ES cell culture media that are free of components derived from humans and animals, for clinical research. This time, Ajinomoto interviewed Prof. Ryuhei Hayashi about important points in clinical research.